DARPin delivers promising results in phase II study of exudative AMD:
September 15th 2014Abicipar pegol was at least as effective as ranibizumab for treatment of exudative age-related macular degeneration, and appeared to have a longer duration of action In a randomized, double-masked phase II study.
Aerie glaucoma eye drop treatment trial commences in Canada
September 9th 2014Dosing has commenced for the first patients enrolled in Aerie Pharmaceuticals’ phase III registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension.
Iluvien receives national marketing authorization in 10th country
September 9th 2014The Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Verteporfin does not improve efficacy of ranibizumab for AMD (VIDEO)
September 5th 2014William Fredette, MD, discusse the results of two trials published in Opthalmology, which indicate that the combination of Verteporfin Photodynamic Therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to AMD. Video provided by The Doctor's Channel.
Correcting radial keratotomy: Refractive epidemic of future
September 1st 2014In this first of a two-part series, Arun C. Gulani, MD, will address the entire corneal aspects of correcting radial keratotomy (RK). The next column will address the lens-based surgeries from phakic to pseudophakic when they are associated with RK correction.
Accommodating IOL: 2 years follow-up
September 1st 2014The Synchrony dual-optic accommodative intraocular lens (Abbott Medical Optics) seems to be clinically safe and effective after 2 years of follow-up. The visual function at intermediate and far improved rapidly postoperatively. Half of patients require a +1 D prescription for near vision.